Threshold Pharmaceuticals has posted early data from the Phase I portion of the investigator-sponsored Phase I/II trial of its investigational hypoxia-targeted drug TH-302 in combination with Avastin (bevacizumab) in patients with recurrent glioblastoma following bevacizumab failure (Study 4003). No dose-limiting toxicity has been reported to date at doses of TH-302 as high as 670 mg/m2 plus bevacizumab at 10 mg/m2 every two weeks. Preliminary data in 14 patients showed TH-302 in combination wi...